Revelation Biosciences (FRA:56U0) Dividends per Share : €0.00 (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Dividends per Share?

Revelation Biosciences's dividends per share for the three months ended in Mar. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Revelation Biosciences's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Revelation Biosciences Dividends per Share Historical Data

The historical data trend for Revelation Biosciences's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Dividends per Share Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividends per Share	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Revelation Biosciences's Dividends per Share

For the Biotechnology subindustry, Revelation Biosciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Dividend Yield % falls into.

Revelation Biosciences Dividends per Share Calculation

Dividends paid to per common share.

Revelation Biosciences (FRA:56U0) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Revelation Biosciences's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-2.321
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Revelation Biosciences Dividends per Share Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines